#USA #Dallas #Koya Medical #Dayspring #Phlebolymphedema

Superior Outcomes for Older Adults and Patients with Phlebolymphedema Using Dayspring

Koya Medical, a leading innovator in medical technology focusing on venous and lymphatic diseases, recently announced some groundbreaking results from their research on Dayspring, a unique mobility-enabled compression therapy. This therapy targets adults aged 65 and older as well as patients suffering from phlebolymphedema, a serious and often debilitating condition.

Study Overview

The new findings stem from two subgroup analyses of the TEAYS randomized controlled trial, which has drawn significant attention for its direct, head-to-head comparison of Dayspring against an advanced pneumatic compression device (APCD). The trial specifically sought to assess limb volume reduction and improvements in disease-specific quality of life metrics in these populations.

Efficacy in Older Adults

In examining how Dayspring impacts older adults, the trial found that:

• - Limb Volume Reduction: Patients using Dayspring experienced an average reduction in limb volume of 353.9 mL, notably higher than the -10.7 mL change seen in those using APCD (p < 0.05).
• - Quality of Life Improvement: Participants reported a significant 1.43-point enhancement on the LYMQOL scale, surpassing the meaningful change threshold. This contrasts sharply with a slight decline of 0.10 points for APCD users (p < 0.05).
• - Treatment Adherence Rates: A staggering 86% of those prescribed Dayspring completed their treatments, compared to only 55% for the APCD group (p < 0.001).
• - Patient Preference: By the end of the study period, 77% of patients indicated a preference for the Dayspring therapy, showcasing higher satisfaction compared to just 23% for the APCD.

Dr. Thomas Maldonado emphasized the importance of mobility in older adults, noting that Dayspring bridges the gap between effective treatment and patient lifestyle needs.

Significant Findings in Phlebolymphedema Patients

For individuals grappling with phlebolymphedema, the findings were equally compelling:

• - Limb Volume Effects: Dayspring users showed an impressive 424.4 mL reduction in limb volume, vastly exceeding the 50.8 mL reduction among APCD users (p = 0.0085).
• - Quality of Life Changes: Patients experienced a 1.39-point enhancement in LYMQOL scores with Dayspring versus just 0.18 points for the APCD cohort (p = 0.01).
• - Adherence Rates: Treatment adherence was also superior, with 81% completion for Dayspring versus 49% for the APCD (p ≤ 0.001).
• - Patient Preference Insights: Following the comparative treatments, an astonishing 85% of participants preferred Dayspring, while merely 15% opted for the APCD.

Dr. Michael Barfield, the principal investigator of the trial, highlighted the need for treatment options that suit the particularity of phlebolymphedema, and the results from Dayspring significantly support clinicians in making informed decisions.

Conclusion

The preliminary results suggest that Dayspring not only offers a marked improvement in clinical outcomes but also significantly enhances treatment adherence and patient satisfaction for older adults and phlebolymphedema patients. As the landscape of mobility-enabled compression therapies continues to develop, these results serve as crucial evidence to guide treatment protocols based on individual patient needs rather than product specifications alone.

Koya Medical continues to lead innovative research with the commitment of advancing patient care and delivering evidence-based solutions for chronic venous and lymphatic diseases. As the understanding of mobility-enabled therapy grows, Dayspring’s acceptance in clinical practices seems promising, potentially revolutionizing how these conditions are managed.